Protein replacement therapy

BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Retrieved on: 
Tuesday, October 27, 2020
Genodermatoses, Health sciences, Branches of biology, Rare diseases, Clinical medicine, Collagen disease, Epidermolysis bullosa dystrophica, Epidermolysis bullosa, Structural proteins, Collagen, type VII, alpha 1, Protein replacement therapy, Therapy

BBP-589 is a potentially disease-modifying rC7 replacement therapy that we hope may improve the skin manifestations as well as the systemic symptoms these patients endure.

Key Points: 
  • BBP-589 is a potentially disease-modifying rC7 replacement therapy that we hope may improve the skin manifestations as well as the systemic symptoms these patients endure.
  • Phoenix Tissue Repair is aBoston-based company that is an affiliate of BridgeBio Pharma and is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB).
  • BBP-589 is an investigational protein replacement therapy which uses a recombinant collagen type VII (rC7) for the treatment of RDEB.
  • Moreover, BridgeBio and Phoenix Tissue Repair operate in very competitive and rapidly changing environments in which new risks emerge from time to time.

Global Epidermolysis Bullosa Pipeline 2020: Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 4, 2020
Pharmaceutical, Health, Clinical trials, Genodermatoses, Rare diseases, Epidermolysis bullosa, RTT, Pipeline, Protein replacement therapy, Junctional epidermolysis bullosa

The "Epidermolysis Bullosa Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epidermolysis Bullosa Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Global Epidermolysis Bullosa market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates.
  • This Epidermolysis Bullosa pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Epidermolysis Bullosa presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Epidermolysis Bullosa pipeline.